Clinical Trials

    A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer (SUNRAY-01)

    Investigator: Jun Zhang

    Study Coordinator: Derek Cole

    Status: Enrolling

    ClinicalTrials.gov Number: NCT06119581

    Phone: 713.441.5607

    Protocol Number: PRO00037985

    Description


    The purpose of this study is to assess if adding LY3537982 in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change in a gene called KRAS G12C. Study participation, including follow-up, could last up to 3 years, depending on how you and your lung cancer are doing.